7.95
price down icon4.67%   -0.40
after-market アフターアワーズ: 7.95
loading
前日終値:
$8.35
開ける:
$8.7
24時間の取引高:
120.74K
Relative Volume:
1.60
時価総額:
$70.27M
収益:
$140.46M
当期純損益:
$-146.34M
株価収益率:
-6.2598
EPS:
-1.27
ネットキャッシュフロー:
$-117.73M
1週間 パフォーマンス:
-11.32%
1か月 パフォーマンス:
-22.19%
6か月 パフォーマンス:
-32.14%
1年 パフォーマンス:
-60.10%
1日の値動き範囲:
Value
$7.885
$8.70
1週間の範囲:
Value
$7.611
$10.38
52週間の値動き範囲:
Value
$7.611
$25.50

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
名前
Karyopharm Therapeutics Inc
Name
セクター
Healthcare (1189)
Name
電話
617-658-0600
Name
住所
85 WELLS AVENUE, NEWTON, MA
Name
職員
279
Name
Twitter
@Karyopharm
Name
次回の収益日
2024-11-05
Name
最新のSEC提出書
Name
KPTI's Discussions on Twitter

KPTI を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
Biotechnology icon
KPTI
Karyopharm Therapeutics Inc
7.95 70.27M 140.46M -146.34M -117.73M -1.27
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
479.79 121.85B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
698.74 76.83B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
624.67 37.96B 1.86B -40.29M -1.28B -0.85
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
246.75 30.69B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
271.80 29.71B 3.32B -860.46M -1.04B -8.32

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-01-19 開始されました Piper Sandler Overweight
2022-11-04 アップグレード RBC Capital Mkts Sector Perform → Outperform
2022-02-09 アップグレード JP Morgan Underweight → Neutral
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-08-06 ダウングレード JP Morgan Overweight → Neutral
2021-08-06 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-08-06 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-07-02 開始されました Morgan Stanley Overweight
2020-03-04 開始されました Barclays Overweight
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-07-23 アップグレード JP Morgan Neutral → Overweight
2019-07-05 繰り返されました H.C. Wainwright Buy
2019-07-05 繰り返されました Robert W. Baird Outperform
2019-03-01 ダウングレード JP Morgan Overweight → Neutral
2019-02-28 繰り返されました BofA/Merrill Underperform
2019-02-27 ダウングレード BofA/Merrill Neutral → Underperform
2019-01-03 アップグレード BofA/Merrill Underperform → Neutral
2018-12-03 開始されました B. Riley FBR Buy
2018-11-09 アップグレード Wedbush Neutral → Outperform
2018-05-24 ダウングレード Wedbush Outperform → Neutral
2018-04-02 再開されました Leerink Partners Outperform
2017-11-15 再開されました H.C. Wainwright Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2016-09-08 繰り返されました H.C. Wainwright Buy
2016-08-30 アップグレード Jefferies Hold → Buy
2016-08-18 開始されました H.C. Wainwright Buy
2016-06-28 開始されました Robert W. Baird Outperform
すべてを表示

Karyopharm Therapeutics Inc (KPTI) 最新ニュース

pulisher
Feb 27, 2025

Karyopharm Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025
pulisher
Feb 26, 2025

Karyopharm Therapeutics Inc.'s SWOT analysis: biotech firm's stock faces pivotal year - Investing.com

Feb 26, 2025
pulisher
Feb 26, 2025

Karyopharm Therapeutics Inc.’s SWOT analysis: biotech firm’s stock faces pivotal year By Investing.com - Investing.com South Africa

Feb 26, 2025
pulisher
Feb 25, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price - Investing.com Australia

Feb 25, 2025
pulisher
Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm enacts reverse stock split to meet Nasdaq standards - Investing.com

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Unveils 1-for-15 Reverse Stock Split, Effective February 25, 2025 - Nasdaq

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Therapeutics to Implement 1-for-15 Reverse Stock Split -February 24, 2025 at 01:18 pm EST - Marketscreener.com

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Announces 1-for-15 Reverse Stock Split - Citizentribune

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm announces 1-for-15 reverse stock split - MSN

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm enacts 1-for-15 reverse stock split to boost price By Investing.com - Investing.com South Africa

Feb 24, 2025
pulisher
Feb 24, 2025

Can Karyopharm's 15:1 Reverse Split Save Its Nasdaq Listing? - StockTitan

Feb 24, 2025
pulisher
Feb 24, 2025

Karyopharm Therapeutics' (KPTI) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Feb 24, 2025
pulisher
Feb 23, 2025

Karyopharm Therapeutics’ (KPTI) “Buy” Rating Reiterated at HC Wainwright - Defense World

Feb 23, 2025
pulisher
Feb 22, 2025

Karyopharm’s 2024 Earnings and Clinical Progress - TipRanks

Feb 22, 2025
pulisher
Feb 21, 2025

Karyopharm targets $1B revenue potential for Selinexor in myelofibrosis amid Phase 3 progress - MSN

Feb 21, 2025
pulisher
Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target By Investing.com - Investing.com South Africa

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm’s Earnings Call: Growth Amid Financial Challenges - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics: Strong Financial Performance and Strategic Developments Justify Buy Rating - TipRanks

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Announces Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 20, 2025
pulisher
Feb 20, 2025

H.C. Wainwright maintains Buy on Karyopharm with $7 target - Investing.com India

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q4 2024 Earnings Call Transcript - Insider Monkey

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Call Highlights: Navigating Revenue ... - Yahoo Finance

Feb 20, 2025
pulisher
Feb 20, 2025

Karyopharm Therapeutics Faces Financial Uncertainty Amid $1.6 Billion Deficit and Urgent Need for Funding - TipRanks

Feb 20, 2025
pulisher
Feb 19, 2025

Karyopharm Therapeutics: Q4 Earnings Snapshot - CT Insider

Feb 19, 2025
pulisher
Feb 19, 2025

Earnings call transcript: Karyopharm Q4 2024 revenue misses forecasts By Investing.com - Investing.com Canada

Feb 19, 2025
pulisher
Feb 19, 2025

Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates - MSN

Feb 19, 2025
pulisher
Feb 19, 2025

Earnings call transcript: Karyopharm Q4 2024 revenue misses forecasts - Investing.com India

Feb 19, 2025
pulisher
Feb 19, 2025

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Previ - GuruFocus.com

Feb 19, 2025
pulisher
Feb 19, 2025

Karyopharm Reports Fourth Quarter and Full Year 2024 Financial Results, Announces Update to Phase 3 XPORT-EC-042 Trial and Highlights Recent Company Progress - Victoria Advocate

Feb 19, 2025
pulisher
Feb 19, 2025

Karyopharm Therapeutics: Q4 Earnings Snapshot -February 19, 2025 at 07:46 am EST - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Karyopharm Therapeutics Inc. SEC 10-K Report - TradingView

Feb 19, 2025
pulisher
Feb 19, 2025

Karyopharm Therapeutics Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 19, 2025
pulisher
Feb 19, 2025

Karyopharm Therapeutics Inc (KPTI) Q4 2024 Earnings Report Preview: What To Look For - Yahoo Finance

Feb 19, 2025
pulisher
Feb 18, 2025

Karyopharm Therapeutics' SWOT analysis: stock potential amid clinical trials - Investing.com India

Feb 18, 2025
pulisher
Feb 18, 2025

Karyopharm Therapeutics' SWOT analysis: stock potential amid clinical trials By Investing.com - Investing.com Nigeria

Feb 18, 2025
pulisher
Feb 18, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Crosses Below 200-Day Moving AverageWhat's Next? - MarketBeat

Feb 18, 2025
pulisher
Feb 14, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Earns "Outperform" Rating from Royal Bank of Canada - MarketBeat

Feb 14, 2025
pulisher
Feb 12, 2025

Karyopharm to Report Fourth Quarter and Full Year 2024 Financial Results on February 19, 2025 - Citizentribune

Feb 12, 2025
pulisher
Feb 11, 2025

Did Karyopharm Therapeutics Inc (KPTI) perform well in the last session? - US Post News

Feb 11, 2025
pulisher
Feb 11, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Given “Outperform” Rating at Royal Bank of Canada - Defense World

Feb 11, 2025
pulisher
Feb 08, 2025

Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Below 200 Day Moving AverageWhat's Next? - MarketBeat

Feb 08, 2025
pulisher
Feb 08, 2025

Karyopharm Therapeutics Inc (NASDAQ: KPTI) Shares Fall By 1.43 Percent In The Past Week, But How Long Will It Last? – Marketing Sentinel - Marketing Sentinel

Feb 08, 2025

Karyopharm Therapeutics Inc (KPTI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Karyopharm Therapeutics Inc (KPTI) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Paulson Richard A.
President and CEO
Feb 04 '25
Sale
0.65
4,099
2,664
1,120,158
Paulson Richard A.
President and CEO
Jan 06 '25
Sale
0.78
4,055
3,175
1,124,257
Paulson Richard A.
President and CEO
Dec 04 '24
Sale
0.81
3,620
2,932
1,128,312
Paulson Richard A.
President and CEO
Nov 05 '24
Sale
0.91
3,675
3,346
1,131,932
Paulson Richard A.
President and CEO
Oct 04 '24
Sale
0.88
3,607
3,172
1,135,607
Mano Michael
SVP, General Counsel&Secretary
Sep 04 '24
Sale
0.72
3,971
2,866
273,881
Paulson Richard A.
President and CEO
Sep 04 '24
Sale
0.72
3,667
2,647
1,139,214
Mason Michael
EVP, CFO & Treasurer
Sep 04 '24
Sale
0.72
7,050
5,089
391,054
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
Sep 04 '24
Sale
0.72
5,356
3,866
404,051
Paulson Richard A.
President and CEO
Aug 06 '24
Sale
0.93
3,608
3,355
1,142,881
$81.55
price up icon 2.95%
$22.68
price down icon 0.31%
$33.64
price up icon 0.63%
$319.86
price down icon 1.18%
$113.03
price up icon 3.89%
biotechnology ONC
$271.80
price down icon 2.56%
大文字化:     |  ボリューム (24 時間):